You are here

Article Text

Article menu
Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
CASE REPORT
Living donor renal transplant in a patient with end-stage renal disease due to Hermansky-Pudlak syndrome
  1. Nassreen Abdullah1,2,
  2. Niall F Davis1,2,
  3. John Quinn3,
  4. Ponnusamy Mohan1,2
  1. 1Royal College of Surgeons in Ireland, Dublin, Ireland
  2. 2Transplant, Urology and Nephrology (TUN), National Kidney Transplant Service, Beaumont Hospital, Dublin, Ireland
  3. 3Haematology, Beaumont Hospital, Dublin, Ireland
  1. Correspondence to Nassreen Abdullah, nassreenabdullah{at}rcsi.ie

Summary

Hermansky-Pudlak syndrome (HPS) is a rare genetic disorder characterised by oculocutaneous albinism, bleeding diathesis and end-stage renal disease (ESRD), due to interstitial deposition of ceroid lipofuscin. Renal transplantation is potentially a definitive treatment option for patients with ESRD due to HPS. Herein, we describe the case of a 55-year-old male patient with HPS that successfully underwent a living donor kidney transplant. We also emphasise the importance of multidisciplinary input during the preoperative, perioperative and postoperative phases in this high-risk clinical scenario.

  • renal transplantation
  • transplantation
  • haematology (incl blood transfusion)
  • urological surgery

https://doi.org/10.1136/bcr-2017-223376

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors PM conception of the case report. NA data collection and drafting and writing up of case report. NFD drafting of case report and critical revision of article. NFD drafting and revising images used. JQ interpretation of haematological tests performed. PM and JQ final approval of the version to be published.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.